Glioma outcomes and benchmark evaluation at HBCHRC, Vizag-GLOBE

Gliomas constitute the most common primary malignant brain tumors and require multidisciplinary management involving surgery, radiotherapy, and chemotherapy. While international guidelines emphasize molecular classification and quality indicators of care, real-world data on patterns of care, treatment compliance, and outcomes from Indian centers remain limited.

This retrospective observational study aims to evaluate patterns of care, quality indicators, treatment compliance, toxicities, and clinical outcomes in patients with glioma treated at Homi Bhabha Cancer Hospital and Research Centre (HBCHRC), Visakhapatnam, between January 2020 and December 2024. The study will benchmark institutional practices against guideline-based standards and identify gaps in care delivery.

Data will be collected from electronic medical records, radiology (PACS), and radiation oncology information systems (ROIS), including demographic details, diagnostic workup, surgical and pathological findings, molecular testing, treatment details, toxicities, follow-up patterns, and disease outcomes. Survival outcomes such as progression-free survival (PFS) and overall survival (OS) will be analyzed, and response assessment will be performed using RANO criteria.

The findings are expected to provide real-world evidence on glioma management, help identify areas for quality improvement, and guide future institutional protocols and research initiatives.